An interventional study of Artificial Intelligence applied to the electrocardiogram to identify left ventricular systolic dysfunction in Heart Failure and Left Ventricular (LV) Systolic Dysfunction, sponsored by Antonio Luiz Pinho Ribeiro. Not yet recruiting at 1 site in Brazil. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Antonio Luiz Pinho Ribeiro · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Heart Failure with a site in Brazil — 37 open to participants now, 46 under way, 20 of them phase 3. Heart Failure · Brazil.
Among the 205 studies in Heart Failure with a site in Brazil, this one is the 18th largest by planned enrollment of the 184 interventional ones that give a count, is one of 11 that started in 2026, is one of 91 with no phase, reaches primary completion later than 30 of the 45 other live ones, and was the 205th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →37 of the 205 studies in Heart Failure with a site in Brazil are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Brazil, United States, Argentina and 29 more countries
Ages 18+
Bayer · Sites in Brazil, United States, Argentina and 20 more countries
Ages up to 18
CAROLINA NIGRO DI LEONE · Sites in Brazil
Ages 18+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 24 more countries
Ages 18+
Bayer · Sites in Brazil, United States, Argentina and 20 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 969 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 23 · Phase 3 65 · Phase 4 15
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,400 is above the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 90 across the 184 interventional studies, 200 across the 19 observational. Of the 103 that completed or were terminated, 36 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 205 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Antonio Luiz Pinho Ribeiro as lead sponsor.
Antonio Luiz Pinho Ribeiro has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
8 of the studies in Heart Failure with a site in Brazil that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07489547Phase 3Hospital de Clinicas de Porto AlegreMedication Withdrawal in Stable HF With Improved LVEF | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 205 studies in Heart Failure with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this parallel-group cluster randomized clinical trial is to evaluate whether opportunistic screening for left ventricular systolic dysfunction (LVSD), using an artificial intelligence algorithm applied to electrocardiograms (AI-ECG), increases the detection of previously unrecognized LVSD among adults aged ≥40 years receiving routine care in primary healthcare centers within the Brazilian Public Health System. LVSD is a key finding in the diagnosis of heart failure with reduced ejection fraction (HFrEF), a condition for which effective guideline-directed medical therapies are available but which remains underdiagnosed and undertreated.
The study will also evaluate the effects of AI-ECG screening on clinical management, healthcare utilization, implementation outcomes, and healthcare costs.
The main questions this study aims to answer are:
Primary healthcare centers will be randomized to either an intervention group, in which AI-ECG screening results will be provided alongside the standard ECG report, or a control group receiving usual care without AI-ECG results.
Participants will:
Background: Cardiovascular diseases (CVD) are the main cause of death in Brazil. Among CVDs, heart failure with reduced ejection fraction (HFrEF) is the main cause of hospitalizations and costs for the public health system (Sistema Único de Saúde, SUS), which still tend to increase with population aging and greater survival rates from acute cardiovascular events. Guideline-directed medical therapy (GDMT) substantially reduces the risk of hospitalization and mortality among patients with HFrEF. Although several recommended therapies are available through the Brazilian Public Health System (SUS), their use remains suboptimal. Part of this is due to the lack of diagnosis, which requires an echocardiogram (ECHO) to diagnose left ventricular systolic dysfunction, an essential finding of HFrEF. ECHO is an expensive and complex exam, and therefore, with restricted access in primary health care (PHC), where patients can wait in lines more than 12 months to undergo an exam. Moreover, asymptomatic LVSD is also a condition that is considered preHF, which has specific GDMT to prevent it from evolving to clinical HFrEF.
The electrocardiogram (ECG) is a screening tool for the evaluation of heart disease and is widely available in primary health care (PHC) centers in Brazil. Although it provides valuable clinical information, conventional ECG interpretation cannot determine left ventricular ejection fraction (LVEF). Sangha et al. demonstrated that a convolutional neural network model can accurately identify left ventricular systolic dysfunction (LVSD) from ECGs. Although this model has been externally validated, including in the community-based ELSA-Brasil cohort, there is currently no evidence that implementing AI-ECG screening for LVSD at scale will change clinical practice.
Implementation outcomes will be assessed using the RE-AIM framework, including reach, effectiveness, adoption, implementation, and maintenance. Capacity-building activities will provide educational resources for healthcare professionals and patients diagnosed with LVSD.
A qualitative component will include PHC physicians and participants to explore barriers and facilitators to AI-ECG implementation. Patients with positive AI-ECG screening results will also be invited to participate, including patients with and without echocardiographically confirmed LVSD. These discussions will explore patients' experiences, feelings, and perceptions regarding AI-ECG screening and its results. Transcripts will be coded, organized into thematic categories, and analyzed using qualitative content analysis. An economic evaluation will assess the cost-effectiveness of AI-ECG screening compared with usual care, incorporating study-specific diagnostic and resource utilization data, Brazilian healthcare costs, and, where feasible, longer-term economic modeling.
Participating primary care centers were selected by the municipal health authorities. For participants, the inclusion criteria are: (1) having an ordered by a primary care physician during routine care; (2) age ≥40 years; (3) no known left ventricular systolic dysfunction ( \<50%); and (4) provision of written . Participants with uninterpretable ECGs will be excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AI-ECG screening results for LVSD will be provided alongside the standard ECG report. AI-ECG results will be generated in real time through an application programming interface (API) connected to Yale University's Cardiovascular Data Science (CarDS) Lab (doi: 10.1161/CIRCULATIONAHA.122.062646). Physicians will be able to request an echocardiogram for patients with a positive AI-ECG screening result, as well as for patients with clinical suspicion of LVSD, defined prior to ECG acquisition. Given the limited availability of echocardiography services and prolonged waiting times in the participating municipalities, the study will provide echocardiograms for all eligible patients patients meeting the referral criteria in either study arm, following same referral procedures.
Diagnostic Test: Artificial Intelligence applied to the electrocardiogram to identify left ventricular systolic dysfunction
The standard ECG report will be provided without AI-ECG screening results. The AI-ECG algorithm will run in the background, but its results will not be disclosed to treating physicians or used to guide clinical decisions during the six-month follow-up period. Physicians will be able to request an echocardiogram for patients with clinical suspicion of LVSD, , defined prior to ECG acquisition. Given the limited availability of echocardiography services and prolonged waiting times in the participating municipalities, the study will provide echocardiograms for all eligible patients meeting the referral criteria, following the same referral procedures as in the intervention group. For ethical reasons, participants in the control group with a positive AI-ECG screening result who have not undergone echocardiography during the study will be offered an echocardiogram after completion of the six-month follow-up period.
AI-ECG results will be generated in real time through an application programming interface (API) connected to Yale University's Cardiovascular Data Science (CarDS) Lab. The AI-ECG algorithm was developed by the Yale CarDS Lab and previously validated for detecting LVSD (Sangha et al. Circulation. 2023;148:765-777. doi: 10.1161/CIRCULATIONAHA.122.062646). A positive AI-ECG screening result will be generated when the predicted probability of LVSD exceeds a predefined threshold of 0.10. This threshold was selected to achieve a sensitivity greater than 90% in the original internal validation study to detect left ventricular ejection fraction (LVEF)\<40%. In the present study, it will be used to detect a LVEF\<50%, as current guidelines uses this threshold for LVSD, which leads to clinical actions.
Proportion of new diagnosis of left ventricular systolic dysfunction
The primary outcome will be the proportion of participants with newly identified left ventricular systolic dysfunction (LVSD), defined as a left ventricular ejection fraction \<50% on echocardiography, within six months of enrollment. The proportion will be calculated as the number of participants with newly identified LVSD divided by the total number of participants enrolled in each study arm. The primary analysis will compare the intervention and control groups according to the intention-to-treat principle, accounting for clustering at the primary healthcare center level.
Time frame: 6 months
Key secondary outcome: Diagnostic yield
Diagnostic yield, calculated as the number of newly identified LVSD cases divided by the number of echocardiograms performed in each study arm. The power assessment was based on data from the pilot study (10 PHC in three municipalities, n=342). Expected event proportions were estimated by combining participants from both study arms and were 2.5% for those with clinical suspicion only, 29.2% for those with a positive AI-ECG and no clinical suspicion, and 26.7% for those with both a positive AI-ECG and clinical suspicion. These estimates correspond to overall expected diagnostic yields of 17.7% for the intervention strategy (clinical suspicion or positive AI-ECG) and 9.25% for clinical suspicion alone. Power was assessed under scenarios including 60 or 74 PHCs, 72 or 100 participants per PHC, and echocardiography completion rates of 80% or or 100%. The estimated statistical power was 100% across all scenarios.
Time frame: 6 months
Number needed to diagnose a LVSD
The number needed to diagnose will be calculated as the number of echocardiograms required to identify one case of LVSD.
Time frame: 6 months
Incremental diagnostic yield
The incremental diagnostic yield will be assessed as the difference between study arms in the number of newly identified LVSD cases per 100 participants.
Time frame: 6 months
Agreement between clinical suspicion and AI-ECG positivity in identifying patients with LVSD
Agreement between clinical suspicion and AI-ECG positivity will be assessed using Cohen's kappa coefficient, with 95% confidence intervals accounting for clustering at the primary healthcare center level. The overlap between the two screening strategies will also be described by calculating the proportions of participants identified exclusively through clinical suspicion, exclusively through AI-ECG positivity, or through both approaches. Among participants who undergo echocardiography, the proportion with confirmed LVSD (LVEF \<50%) will be calculated for each subgroup to assess the diagnostic yield of the different screening strategies.
Time frame: 6 months
Implementation outcome: Reach
Reach will be assessed as the proportion of eligible individuals who agree to participate in the study.
Time frame: 6 months
Implementation outcome: Effectiveness
Effectiveness will be evaluated based on the primary study outcome, defined as the proportion of participants with newly identified left ventricular systolic dysfunction (LVSD) within six months.
Time frame: 6 months
Implementation outcome: Adoption
Adoption will be assessed as the proportion of physicians who request an echocardiogram after it is offered, stratified by the indication for echocardiography.
Time frame: 6 months
Implementation outcome: Implementation
Implementation will be evaluated through: (1) the proportion of indicated echocardiograms that are performed, (2) the proportion of participants with confirmed LVSD (left ventricular ejection fraction \<50%) whose diagnosis is documented in the primary health center's electronic health record, and (3) the proportion of participants with confirmed LVSD who receive appropriate treatment, defined as initiation or optimization of guideline-directed medical therapy (GDMT). ACE inhibitors/ARBs and beta-blockers will be the primary treatment indicators, given their recommendations for LVSD even if asymptomatic, as well as their availability in Brazilian public health system. Other recommended therapies, including ARNIs, MRAs, and SGLT2 inhibitors, will also be assessed according to clinical indications and availability. These outcomes will be stratified by the indication for echocardiography (positive AI-ECG screening result or clinical suspicion).
Time frame: 6 months
Implementation outcome: Maintenance
Maintenance will be assessed by comparing the proportion of indicated echocardiograms that are completed during the first three months versus the last three months of participant enrollment. Analyses will be conducted stratified by the indication for echocardiography (positive AI-ECG screening result or clinical suspicion)
Time frame: 6 months
Exploratory: Diagnosis performance of AI-ECG for LVSD only vs. Clinical suspicion only
Exploratory analyses will be performed for the primary outcome and the secondary outcomes 2, 3, and 4 by comparing participants with positive AI-ECG screening results in the intervention arm with those referred for echocardiography exclusively on the basis of clinical suspicion in the control arm.
Time frame: 6 months
Exploratory: Hospitalizations and deaths
Among participants newly diagnosed with left ventricular systolic dysfunction (LVSD), number and proportion of all-cause hospitalizations and all-cause mortality will be assessed during the six-month follow-up period using standardized questionnaires administered by digital tools and review of administrative data at the municipality's level. Information on hospitalizations will include the occurrence, date, and reason for admission, if available. Hospitalization and mortality outcomes will be compared between the intervention and control groups, accounting for the cluster-randomized study design.
Time frame: 6 months
Evaluation of short educational videos by healthcare providers and patients
Videos will be evaluated by a simplified question if they were useful, with a binary answer, followed by a rank from 1 to 10.
Time frame: 6 months
Acceptability of AI-ECG Screening Among Healthcare Professionals
Healthcare professionals' perceptions of the acceptability of AI-ECG screening will be explored through focus groups. Data will be analyzed using thematic analysis to identify perceived benefits, concerns, and experiences with the screening strategy.
Time frame: 6 months
Barriers and Facilitators to AI-ECG Implementation
Barriers and facilitators to implementing AI-ECG screening in primary healthcare will be explored through focus groups with healthcare professionals and other relevant stakeholders. Data will be analyzed thematically to identify factors influencing implementation.
Time frame: 6 months
Budget Impact of AI-ECG Screening
The budget impact of implementing AI-ECG screening in Brazilian primary healthcare will be estimated by comparing projected healthcare expenditures with and without the screening strategy, including screening, confirmatory testing, treatment, and potential downstream healthcare costs.
Time frame: Six-month trial data informing longer-term budget impact projections
Cost-Effectiveness of AI-ECG Screening
Cost-effectiveness will be assessed by comparing opportunistic AI-ECG screening with usual care in Brazilian primary healthcare. The analysis will include the costs of AI-ECG screening, confirmatory echocardiography, and subsequent clinical management, using study-specific data and Brazilian microcosting studies. Potential long-term reductions in disease progression and associated healthcare costs will be estimated using evidence from published clinical trials. If available, study data on heart failure hospitalizations, emergency visits, and cardiovascular mortality will inform medium- and long-term projections using Markov models or microsimulation. The analysis will estimate the potential cost savings and health benefits associated with earlier LVSD detection and treatment.
Time frame: Six-month follow-up, with medium- and long-term projections based on economic modeling.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available beginning 12 months after publication of the primary study results and will remain available for 5 years.
Access criteria: De-identified individual participant data underlying the results reported in the primary publication, including relevant baseline characteristics, ECG findings, echocardiographic results, and study outcomes, will be available upon reasonable request, subject to approval by the study investigators and applicable ethical and data protection requirements.
Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 15 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.